A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
about
A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... to moderate plaque psoriasis.
@en
A randomized, double-blind, pl ...... to moderate plaque psoriasis.
@nl
type
label
A randomized, double-blind, pl ...... to moderate plaque psoriasis.
@en
A randomized, double-blind, pl ...... to moderate plaque psoriasis.
@nl
prefLabel
A randomized, double-blind, pl ...... to moderate plaque psoriasis.
@en
A randomized, double-blind, pl ...... to moderate plaque psoriasis.
@nl
P2093
P2860
P356
P1476
A randomized, double-blind, pl ...... to moderate plaque psoriasis.
@en
P2093
P2860
P304
P356
10.1111/JDV.14128
P577
2017-02-17T00:00:00Z